



CORRESPONDENCE

Response to the comment on “Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients”

British Journal of Cancer (2020) 123:1468; <https://doi.org/10.1038/s41416-020-1014-4>

We thank De Marco et al. for their valuable comments regarding TFF1, one of the biomarkers in our panel for early detection of pancreatic adenocarcinoma (PDAC).

We concur with the authors that TFF1 plays an important role in this malignancy, and find the information on the importance of copper binding to TFF1 of great interest. We have previously reported on deregulation of several proteins that bind copper in PDAC,^{1,2} and increased levels of this metal element have previously been described in both tissue and serum of patients with pancreatic malignancy.^{3,4} In fact, tissue copper levels were also found to be negatively associated with patient’s survival.⁴ This is not particularly surprising, considering the important role of this metal in cancer, as increased intra-tumoural copper and/or altered systemic copper distribution was shown to play an important role in cancer growth, angiogenesis, motility and metastases. In that respect, targeting copper in cancer therapy⁵ and testing metal complexes based on copper as a novel therapeutic approach (of note, platinum-based chemotherapy has been in use for over 40 years!), as highlighted by the authors, appears to be very promising.

Furthermore, we have recently reported that metal disbalance in PDAC can be detected via deregulated levels of several metals in urine, including increased level of urinary copper, which may potentially serve as a diagnostic and/or prognostic marker in pancreatic cancer.⁶ Thus, mechanistic studies on the effects of copper and its binding partners, as well as testing the potential of copper as novel therapeutic and a potential biomarker seem highly warranted.

AUTHOR CONTRIBUTIONS

Paper writing: O.B. and T.C.J.

ADDITIONAL INFORMATION

Ethics approval and consent to participate Not applicable.

Consent to publish Not applicable.

Data availability Not applicable.

Competing interests The authors declare no competing interests.

Funding information Not applicable.

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Oleg Blyuss ^{1,2,3} and Tatjana Crnogorac-Jurcevic ⁴
¹*School of Physics, Astronomy and Mathematics, University of Hertfordshire, Hatfield, UK;* ²*Department of Paediatrics and Paediatric Infectious Diseases, Sechenov First Moscow University, Moscow, Russia;* ³*Department of Applied Mathematics, Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia and* ⁴*Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK*
Correspondence: Oleg Blyuss (o.blyuss@qmul.ac.uk)

REFERENCES

- Crnogorac-Jurcevic, T., Gangeswaran, R., Bhakta, V., Capurso, G., Lattimore, S., Akada, M. et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. *Gastroenterology* **129**, 1454–1463 (2005).
- Crnogorac-Jurcevic, T., Missiaglia, E., Blaveri, E., Gangeswaran, R., Jones, M., Terris, B. et al. Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. *J. Pathol.* **201**, 63–74 (2003).
- Lener, M. R., Scott, R. J., Wiechwska-Kozłowska, A., Serrano-Fernandez, P., Baszuk, P., Jaworska-Bieniek, K. et al. Serum concentrations of selenium and copper in patients diagnosed with pancreatic cancer. *Cancer Res. Treat.* **48**, 1056–1064 (2016).
- Yu, Z., Zhou, R., Zhao, Y., Pan, Y., Liang, H., Zhang, J. S. et al. Blockage of SLC31A1-dependent copper adsorption increases pancreatic cancer cell autophagy to resist cell death. *Cell Prolif.* **52**, 12568 (2019).
- Denoyer, D., Masaldan, S., La Fontaine, S. & Cate, M. A. Targeting copper in cancer therapy: ‘Copper That Cancer’. *Metallomics* **7**, 1459–1476 (2015).
- Schilling, K., Larner, F., Saad, A., Roberts, R., Kocher, H. M., Blyuss, O. et al. Urine metallomics signature as an indicator of pancreatic cancer. *Metallomics* **12**, 752–757 (2020).

Received: 22 June 2020 Revised: 1 July 2020 Accepted: 16 July 2020
Published online: 3 August 2020